NCT02232399View on ClinicalTrials.gov

Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 15, 2014

Primary Completion Date

April 25, 2017

Study Completion Date

April 25, 2017

Conditions
Congenital Heart Defects
Interventions
DRUG

Levosimendan

The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.

DRUG

Milrinone

The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.

Trial Locations (2)

FIN-00029 HYKS

Children´s Hospital, Helsinki University Central Hospital, Helsinki

416 85

Queen Silvia Children´s Hospital, Gothenburg

All Listed Sponsors
collaborator

Helsinki University Central Hospital

OTHER

lead

Göteborg University

OTHER

NCT02232399 - Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease? | Biotech Hunter | Biotech Hunter